These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 24462284)

  • 21. Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei.
    Govaerts K; Chandrakumaran K; Carr NJ; Cecil TD; Dayal S; Mohamed F; Thrower A; Moran BJ
    Eur J Surg Oncol; 2018 Sep; 44(9):1371-1377. PubMed ID: 30017331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
    BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
    Alexander-Sefre F; Chandrakumaran K; Banerjee S; Sexton R; Thomas JM; Moran B
    Colorectal Dis; 2005 Jul; 7(4):382-6. PubMed ID: 15932563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of an inguinal hernia in patients with pseudomyxoma peritonei.
    Sugarbaker PH
    Eur J Surg Oncol; 2017 Jun; 43(6):1083-1087. PubMed ID: 28131668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
    Iversen LH; Rasmussen PC; Hagemann-Madsen R; Laurberg S
    Colorectal Dis; 2013 Jul; 15(7):e365-72. PubMed ID: 23458368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.
    Järvinen P; Ristimäki A; Kantonen J; Lepistö A
    Scand J Surg; 2013; 102(3):145-51. PubMed ID: 23963027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
    Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
    Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
    Klaver YL; Chua TC; Verwaal VJ; de Hingh IH; Morris DL
    J Surg Oncol; 2013 May; 107(6):585-90. PubMed ID: 23280508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
    Lu YY; Guo AT; Liu AJ; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
    Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking.
    Riss S; Chandrakumaran K; Dayal S; Cecil TD; Mohamed F; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):392-5. PubMed ID: 25238953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
    JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
    Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
    Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
    Dayal S; Taflampas P; Riss S; Chandrakumaran K; Cecil TD; Mohamed F; Moran BJ
    Dis Colon Rectum; 2013 Dec; 56(12):1366-72. PubMed ID: 24201390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.
    Kung V; Delisle M; Alves S; Mohamed F; Cecil T; Moran B
    Eur J Surg Oncol; 2023 Nov; 49(11):107045. PubMed ID: 37677915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.